Bharat Biotech starts human trials of Covid-19 vaccine in PGI Rohtak
Bharat Biotech got the country's drug regulator's approval to start clinical trials of its anti-Corona vaccine Covaxin recently
 "Bharat Biotech starts human trials of Covid-19 vaccine in PGI Rohtak")
premium
The human trial of Bharat Biotech's anti-Covid-19 vaccine Covaxin began at Rohtak's Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij tweeted.
Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today, Vij, who is also the Home and Science & Technology minister said.
Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects, Vij further said in his tweet.
Bharat Biotech got the country's drug regulator's approval to start clinical trials of its anti-Corona vaccine Covaxin recently.
There are over seven anti-corona vaccines at various stages of development in the country with two of them having received the drug regulator's go-ahead to start the human clinical trials of their vaccines.
Earlier this month, Zydus had said it has received approval from authorities to start human trials for its anti-Covid-19 vaccine.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%